Recently developed process intensification has allowed manufacturers increased product output. These output achievements require increased production efficiency and input, pushing many bioreactor systems past their limits. S.U.B. quality requirements, robustness, and functional performance can all become constraints. An effective single-use bioreactor must be able to scale up their process with minimal process changes to meet demand for commercial therapeutics.